The expansion is related to a new market that Boston Scientific expects to enter in a matter of weeks—drug-coated stents. The Natick, MA-based company is on the verge of getting approval from the federal Food and Drug Administration to sell the Taxus stent in the US. Many Wall Street analysts predict Boston Scientific could quickly dominate the market. They also expect the overall market segment could soon grow to $5 billion next year.
FDA Inspectors arrived this week to visit Boston Scientific's operations in the Twin Cities—one of the final steps in the process to approve its new drug-coated stent. The company could get approval in the next two to six weeks, says Thomas Gunderson, a securities analyst with U.S. Bancorp Piper Jaffray.
Want to continue reading?
Become a Free ALM Digital Reader.
Once you are an ALM Digital Member, you’ll receive:
- Breaking commercial real estate news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical coverage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
*May exclude premium content© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
